According to a recent report in , researchers may have discovered a new treatment for neuroendocrine , the most fatal subtype of prostate cancer that occurs in less than 2% of men. The more common prostate adenocarcinoma can also progress into neuroendocrine prostate cancer, which has a bleak ...
known as lineage plasticity, allows prostate cancer cells to transform from adenocarcinoma into neuroendocrine prostate cancer, a much more aggressive and deadly form of the
Normally, the DPYSL5 protein regulates the development of neurons in the brain and is not expressed in other parts of the body. However, the researchers now found that antiandrogen treatment caused the DPYSL5 protein to be expressed in prostate cancer cells. As a result, these cells acquired...
text>Neuroendocrine prostate cancer (NEPC) mostly occurs as a treatment-emergent adaptive response under the pressure of intensive androgen deprivation treatment (t-NEPC). Approximately 30-40% of patients with metastatic castration-resistant prostate cancer (mCRPC) also have neuroendocrine involvement. In...
Uses radiation to damage and kill cancer cells It can also help manage the symptoms they cause. Will it Work for You? Before you begin Lutathera treatment, you’ll meet with a nuclear medicine doctor. We’ll take several scans taken of your body. These scans, along with your medical histo...
Defects in homologous recombination repair genes, such as BRCA1/2, are also being increasingly detected in individuals with advanced prostate cancer. We present the case of a 65-yr-old man with a germline BRCA2 mutation who developed explosive treatment-emergent, small-cell neuroendocrine prostate ...
Aparicio, A. M. et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers.Clin. Cancer Res. Google Scholar Cancer Res.66 ArticleCASGoogle Scholar Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cance...
Neuroendocrine prostate cancer (NEPC) encompasses various clinical contexts, ranging from the de novo presentation of small cell prostatic carcinoma to a treatment-emergent transformed phenotype that arises from typical adenocarcinoma of the prostate. The development of resistance to potent androgen receptor...
Neuroendocrine prostate cancer (NEPC) is a highly lethal variant of castration-resistant prostate cancer (CRPC) with poor survival rates. Current treatment options for NEPC are limited to highly toxic platinum drugs highlighting the urgent need for new therapies. This study aimed to develop a novel...
Cell culture and treatment LNCaP, NCI-H660, and PC3 cell lines were obtained from the American Type Culture Collection (ATCC). V16A was established by Dr. Amina Zoubeidi’s laboratory. All prostate cancer cell lines were cultured as recommended by ATCC. No mycoplasma contamination was detected...